The global preterm birth and prom testing market size is expected to reach USD 1.3 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.8% during the forecast period. Rising incidence of preterm births, increasing geographical reach by market players, high demand for effective diagnosis of preterm births, and advanced drug delivery devices are expected to drive the market.
Every year, approximately 15 million babies around the world are born before the 37th week of pregnancy and this number is expected to increase further. Around 1 million children die each year due to complications caused by preterm births. Premature Rupture of Membranes (PROM) causes about 4.5 million preterm births each year, worldwide. Globally, preterm birth is among the most frequent causes of death among neonates within the first month of life.
Increasing average age of pregnant women (>35 years of age) has led to an increase in the risk of heath conditions such as high blood pressure and reduced blood flow to the placenta. These issues risk the health of both mother and unborn child and often result in preterm births or neonatal deaths. Even though traditional methods such as Nitrazine and Ferning test make it possible to obtain a negative predictive value (NPV), they have extremely poor positive predictive values for spontaneous deliver. The approval of PartaSure (Parsagen Diagnostics, Inc. and Qiagen) in April 2018 and other improved diagnostic test kits has introduced a highly efficacious yet cost-effective options for PROM testing in symptomatic patients.
Request a free sample copy or view report summary: Preterm Birth and PROM Testing Market Report
Preterm Birth and PROM Testing Market Report Highlights
Based on test type, the PAMG1 immunoassay segment is expected to witness lucrative growth over the forecast period driven by rapid uptake of these test kits in developed markets
Improved PROM diagnostic methods are increasingly replacing traditional standard-of-care tests (Ferning and Nitrazine), supported by their ease of use and high sensitivity
North America dominated the market with the largest share in 2017. Focus on early diagnosis of women’s health issues, along with improved awareness about preterm birth and PROM testing, are responsible for the dominance of this region
Strong unmet needs, rising awareness regarding maternal health, and uptake of improved diagnostic methods are expected to propel the growth of the preterm labor and PROM testing market
Some of the key players in the market are Qiagen, Hologic, Cooper Surgical, Abbott Laboratories, Medixbiochemica, Sera Prognostics, Biosynex, and IQ Products.
Preterm Birth and PROM Testing Market Segmentation
Grand View Research has segmented the global preterm birth and PROM testing market based on test type and region:
Preterm Birth and PROM Testing Test Type Outlook (Revenue, USD Million, 2014 - 2025)
Pooling (Speculum Exam)
IL-1, IL-2, IL-8, TNF-a
AFP (Alpha fetoprotein)
Preterm Birth and PROM Testing Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.